Dynamics of Reverse Transcription-Polymerase Chain Reaction and Serologic Test Results in Children with SARS-CoV-2 Infection.


Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
02 2022
Historique:
received: 02 07 2021
revised: 10 09 2021
accepted: 17 09 2021
pubmed: 28 9 2021
medline: 5 2 2022
entrez: 27 9 2021
Statut: ppublish

Résumé

To determine the time to reverse transcription-polymerase chain reaction (RT-PCR) negativity after the first positive RT-PCR test, factors associated with longer time to RT-PCR negativity, proportion of children seroconverting after proven severe acute respiratory syndrome coronavirus 2 infection, and factors associated with the lack of seroconversion. The Epidemiological Study of Coronavirus in Children of the Spanish Society of Pediatrics is a multicenter study conducted in Spanish children to assess the characteristics of coronavirus disease 2019. In a subset of patients, 3 serial RT-PCR tests on nasopharyngeal swab specimens were performed after the first RT-PCR test, and immunoglobulin G serology for severe acute respiratory syndrome coronavirus 2 antibodies was performed in the acute and follow-up (<14 and ≥14 days after diagnosis) phase. In total, 324 patients were included in the study. The median time to RT-PCR negativity was 17 days (IQR, 8-29 days), and 35% of patients remained positive more than 4 weeks after the first RT-PCR test. The probability of RT-PCR negativity did not differ across groups defined by sex, disease severity, immunosuppressive drugs, or clinical phenotype. Globally, 24% of children failed to seroconvert after infection. Seroconversion was associated with hospitalization, persistence of RT-PCR positivity, and days of fever. Time to RT-PCR negativity was long, regardless of the severity of symptoms or other patient features. This finding should be considered when interpreting RT-PCR results in a child with symptoms, especially those with mild symptoms. Seroprevalence and postimmunization studies should consider that 11 in 4 infected children fail to seroconvert.

Identifiants

pubmed: 34571020
pii: S0022-3476(21)00905-7
doi: 10.1016/j.jpeds.2021.09.029
pmc: PMC8463102
pii:
doi:

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

126-132.e3

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Alfredo Tagarro (A)

Pediatrics Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain; Pediatrics Research Group, Europea University of Madrid, Madrid, Spain; Fundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain.

Francisco José Sanz-Santaeufemia (FJ)

Pediatrics Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.

Carlos Grasa (C)

Pediatrics, Infectious and Tropical Diseases Department, Hospital Universitario La Paz, Instituto Investigación Hospital La Paz (IDIPaz), Madrid, Spain.

Elena Cobos (E)

Fundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain.

Julia Yebra (J)

Pediatrics Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.

Jose Antonio Alonso-Cadenas (JA)

Emergency Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.

Fernando Baquero-Artigao (F)

Pediatrics, Infectious and Tropical Diseases Department, Hospital Universitario La Paz, Instituto Investigación Hospital La Paz (IDIPaz), Madrid, Spain.

Juan Miguel Mesa-Guzmán (JM)

Pediatrics Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.

Beatriz Pérez-Seoane (B)

Pediatrics Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.

Cristina Calvo (C)

Pediatrics, Infectious and Tropical Diseases Department, Hospital Universitario La Paz, Instituto Investigación Hospital La Paz (IDIPaz), Madrid, Spain.

María Luisa Herreros (ML)

Pediatrics Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.

Cristina Epalza (C)

Fundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain; Pediatrics Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Susana Melendo (S)

Infectious Diseases and Pediatric Immunology Unit, Department of Pediatrics, Hospital Universitario Vall d'Hebron, Madrid, Spain.

Sara Dominguez-Rodriguez (S)

Fundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain.

Paula Vidal (P)

Pediatrics Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Aragón, Spain.

Mónica Pacheco (M)

Pediatrics Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.

Alvaro Ballesteros (A)

Fundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain.

María Bernardino (M)

Pediatrics Research Group, Europea University of Madrid, Madrid, Spain.

Sara Villanueva-Medina (S)

Pediatrics Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Paula Rodríguez-Molino (P)

Pediatrics, Infectious and Tropical Diseases Department, Hospital Universitario La Paz, Instituto Investigación Hospital La Paz (IDIPaz), Madrid, Spain.

Sandra Miragaya Castro (S)

Emergency Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.

Jacques Rivière (J)

Infectious Diseases and Pediatric Immunology Unit, Department of Pediatrics, Hospital Universitario Vall d'Hebron, Madrid, Spain.

Rosa Garcés (R)

Pediatrics Department, Hospital Clínico Universitario Lozano Blesa Zaragoza, Aragón, Spain.

Begoña Santiago (B)

Pediatric Infectious Diseases Unit. Department of Pediatrics, Hospital Universitario Gregorio Marañón, Madrid, Spain.

Victoria Fumadó (V)

Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Universitario Sant Joan de Deu Barcelona, Barcelona, Spain.

María Urretavizcaya-Martínez (M)

Pediatrics Department, Complejo Hospitalario de Navarra, Pamplona, Spain.

María Luz García-García (ML)

Pediatrics Department, Hospital Universitario Severo Ochoa Madrid, Madrid, Spain.

María Penín (M)

Pediatrics Departament, Hospital Universitario Príncipe de Asturias, Madrid, Spain.

Fernando Cava (F)

Microbiology Department, UR Salud, Hospital Universitario Infanta Sofía, Madrid, Spain.

Elena Sáez (E)

Microbiology Department, UR Salud, Hospital Universitario Infanta Sofía, Madrid, Spain.

María Isabel Iglesias-Bouzas (MI)

Pediatric Intensive Care Unit, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.

Blanca Herrero (B)

Oncology Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.

Teresa de Jesús Reinoso (TJ)

Pediatrics Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain. Electronic address: treinosol@gmail.com.

Cinta Moraleda (C)

Fundación de Investigación Biomédica Hospital 12 de Octubre. Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain; Pediatrics Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH